Exo-aza spiro inhibitors of menin-MLL interaction

US11396517B1 · kind B1 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Xuedong Dai · San Jose, US
• Olivier Alexis Georges Querolle · Évreux, FR
• Daniel Jason Krosky · Blue Bell, US
• Wei CAI · Shanghai, CN
• Liqiang FU · Shanghai, CN
• Linglong KONG · Shanghai, CN
• Yingtao LIU · Shanghai, CN
• Zhao-Kui Wan · Lexington, US
• Barbara Morschhäuser Geb. Herkert · Beerse, BE
• Vineet Pande · Vosselaar, BE
• James P. Edwards · San Diego, US
• Aaron Nathaniel Patrick · Doylestown, US
• Patrick René Angibaud · Louviers, FR
• Virginie Sophie Poncelet · Rodez, FR

Key dates

• Filing date: Dec 19, 2018
• Grant date: Jul 26, 2022
• Expiry date: Jan 24, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.